Welcome to our dedicated page for Bruker news (Ticker: BRKR), a resource for investors and traders seeking the latest updates and insights on Bruker stock.
Bruker Corporation (Nasdaq: BRKR) regularly issues news and updates on its activities in scientific instruments, diagnostics, superconducting technologies, and advanced research collaborations. This news page aggregates company press releases and third-party coverage so readers can review developments affecting Bruker’s analytical instruments, diagnostic solutions, and related businesses.
Recent announcements highlight multi-year orders in the Bruker Energy & Supercon Technologies (BEST) division for high-performance superconductors used in MRI magnets, including materials that support helium-free MRI magnet architectures. News items also cover orders for high-field NMR and EPR systems from leading European research institutions for materials science, battery research, and disease biology, illustrating how Bruker’s magnetic resonance systems are deployed in academic and government research environments.
Bruker’s news flow also reflects its expansion in applied mass spectrometry and diagnostics. The company has reported the consolidation of full ownership of TOFWERK AG, adding ultra-fast time-of-flight mass spectrometry for real-time air and semiconductor cleanroom monitoring, atmospheric chemistry research, exposomics, and food, flavors and fragrances testing. It has also been associated with the acquisition of AST Revolution, an in vitro diagnostics company focused on rapid antimicrobial susceptibility testing (AST) solutions built around the WAVE and Arc systems.
Investors and researchers following BRKR news can expect updates on earnings releases and financial guidance, capital structure developments such as preferred stock offerings and dividends, board and governance changes, and strategic transactions. This page is a convenient entry point for tracking how Bruker’s instruments, diagnostics, and superconducting technologies are being adopted across life sciences, applied markets, industrial and cleantech research, and semiconductor-related applications.
Bruker has completed the acquisition of NanoString Technologies, Inc., for approximately $392.6 million, acquiring assets such as nCounter®, GeoMx®, CosMx™, and AtoMx™ product lines. The acquisition aims to enhance gene expression analysis and spatial transcriptomics for research purposes. NanoString generated revenues of $168 million in 2023 and has been important in supporting discovery, translational, and pre-clinical disease research with over 7,000 publications.
Bruker has completed the acquisition of ELITechGroup for €870 million in cash, excluding the clinical chemistry business, becoming a leading infectious disease specialist in the in-vitro diagnostics market. ELITech offers innovative sample-to-answer systems and assays for molecular diagnostics, with FY 2023 revenue of approximately EUR 150 million.
Bruker (BRKR) reported strong Q1 2024 financial results with revenues of $721.7 million, up 5.3% yoy. GAAP EPS was $0.35, non-GAAP EPS $0.53. FY 2024 guidance raised to $3.29-$3.35 billion, implying 11%-13% yoy growth. Acquisition of ELITech expected to boost revenue and EPS.
FAQ
What is the current stock price of Bruker (BRKR)?
What is the market cap of Bruker (BRKR)?
